BridgeBio Pharma has scrapped plans to buy out its subsidiary Eidos Therapeutics. The planned deal hit a wall when a special committee set up by Eidos turned down BridgeBio’s third and final offer.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,